Telesta Therapeutics Inc. (BNC)

[BioSpecialist]

PHASE 3 SUCCESS IN BLADDER CANCER YIPPIIIIII

PHASE 3 SUCCESS FOR BIONICHE (BNC.TO) .LOAD UP THE TRUCK WE HAVE A HUGE WINNER HERE .MARKET CAP OF 120 MIL$ IS RIDICULOUS .

BNC.TO WILL BE THE NEXT BIG CASH COW .


http://finance.yahoo.com/news/UrocidinTM-Phase-III-Trial-prnews-3143154188.html?x=0&.v=11

Urocidin(TM) Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo

The current milestone payment was triggered by Urocidin™ attaining a contractual efficacy goal from an ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial. Urocidin™ is a product for non-muscle-invasive bladder cancer that is refractory to current first-line therapy. The clinical trial providing results was initiated in late 2006, prior to the execution of the agreement between the parties.